{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Adverse events assessed at all subject visits by interviews with the subject and the subject's parent/ primary caregiver.","groups":[{"description":"Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.","id":"OG000","title":"Arm I - Methylphenidate Hydrochloride"},{"description":"Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.","id":"OG001","title":"Arm II -Modafinil"},{"description":"Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.","id":"OG002","title":"Arm III Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"29 days","title":"Adverse Events","type":"SECONDARY","unitOfMeasure":"events"}